3606 Background: Fluoropyrimidines, although generally well tolerated, can induce life-
threatening toxicity. The major known cause of intolerance is deficiency of the detoxifying …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Background Fluoropyrimidines are used in chemotherapy combinations for multiple cancers.
Deficient dihydropyrimidine dehydrogenase activity can lead to severe life‐threatening …

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD)
encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to …

Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …

Purpose Dihydropyrimidine dehydrogenase (DPD) is a critical determinant of 5-fluorouracil
pharmacology, and reduced activity of DPD as a result of deleterious polymorphisms in the …

Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …

Carriers of the genetic DPYD* 2A variant, resulting in dihydropyrimidine dehydrogenase
deficiency, are at significantly increased risk of developing severe fluoropyrimidine …

Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step in fluoropyrimidines
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …

Fluoropyrimidines are frequently used anti‐cancer drugs. It is known that patients with
reduced activity of dihydropyrimidine dehydrogenase (DPD), the key metabolic enzyme in …